• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range.

作者信息

Gallego Pilar, Vilchez Juan Antonio, Lane Deirdre A

出版信息

Circulation. 2013 Jun 4;127(22):2163-5. doi: 10.1161/CIRCULATIONAHA.113.003132. Epub 2013 May 2.

DOI:10.1161/CIRCULATIONAHA.113.003132
PMID:23640972
Abstract
摘要

相似文献

1
Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range.阿哌沙班与华法林用于心房颤动卒中预防的比较：治疗范围内时间的影响
Circulation. 2013 Jun 4;127(22):2163-5. doi: 10.1161/CIRCULATIONAHA.113.003132. Epub 2013 May 2.
2
Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation".
Circulation. 2014 Jan 14;129(2):e21-2. doi: 10.1161/CIRCULATIONAHA.113.005709.
3
Letter by Replogle and Moore regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation".
Circulation. 2014 Jan 14;129(2):e20. doi: 10.1161/CIRCULATIONAHA.113.005092.
4
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.比较不同国际标准化比值（INR）控制水平下，用于预防心房颤动中风的阿哌沙班与华法林的疗效和安全性。
Circulation. 2013 Jun 4;127(22):2166-76. doi: 10.1161/CIRCULATIONAHA.112.142158. Epub 2013 May 2.
5
Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.服用阿哌沙班或华法林的房颤患者的大出血：ARISTOTLE 试验（阿哌沙班用于减少房颤中的中风和其他血栓栓塞事件）：预测因素、特征和临床结局。
J Am Coll Cardiol. 2014 May 27;63(20):2141-2147. doi: 10.1016/j.jacc.2014.02.549. Epub 2014 Mar 19.
6
Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.房颤患者中多药联合治疗及阿哌沙班与华法林的疗效比较：ARISTOTLE试验的事后分析
BMJ. 2016 Jun 15;353:i2868. doi: 10.1136/bmj.i2868.
7
Shared risk factors for anticoagulation in nonvalvular atrial fibrillation: a dilemma in clinical decision making.
J Am Coll Cardiol. 2014 May 27;63(20):2148-2150. doi: 10.1016/j.jacc.2014.02.546. Epub 2014 Mar 19.
8
High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.高敏肌钙蛋白 I 用于评估房颤患者的风险：来自阿哌沙班用于心房颤动减少卒中和其他血栓栓塞事件（ARISTOTLE）试验的见解。
Circulation. 2014 Feb 11;129(6):625-34. doi: 10.1161/CIRCULATIONAHA.113.006286. Epub 2013 Nov 13.
9
ACP Journal Club. In AF, apixaban reduced stroke or systemic embolism compared with warfarin, regardless of patient age.
Ann Intern Med. 2014 Jun 17;160(12):JC7. doi: 10.7326/0003-4819-160-12-201406170-02007.
10
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.接受阿哌沙班或华法林治疗的心房颤动患者主要出血的临床结局和管理：来自 ARISTOTLE 试验的见解。
Eur Heart J. 2015 May 21;36(20):1264-72. doi: 10.1093/eurheartj/ehu463. Epub 2014 Dec 12.

引用本文的文献

1
Rosendaal linear interpolation method appraising of time in therapeutic range in patients with 12-week follow-up interval after mechanical heart valve replacement.罗森达尔线性插值法对机械心脏瓣膜置换术后随访间隔为12周的患者在治疗范围内的时间进行评估。
Front Cardiovasc Med. 2022 Sep 9;9:925571. doi: 10.3389/fcvm.2022.925571. eCollection 2022.
2
Development of an interview-based warfarin nomogram predicting the time spent in the therapeutic INR range: A cost-effective, and non-invasive strategy building from a cross sectional study in a low resource setting.基于访谈的华法林剂量图表的开发，用于预测处于治疗性国际标准化比值（INR）范围内的时间：一种基于低资源环境下横断面研究的具有成本效益的非侵入性策略。
Indian Heart J. 2022 May-Jun;74(3):245-248. doi: 10.1016/j.ihj.2022.03.008. Epub 2022 Mar 25.
3
Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.年龄对华法林剂量、抗凝控制和出血风险的影响。
Pharmacotherapy. 2018 Jun;38(6):588-596. doi: 10.1002/phar.2089. Epub 2018 Feb 27.
4
Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users.非裔美国人和欧裔美国人华法林使用者的抗凝控制质量及出血风险
Pharmacogenet Genomics. 2017 Oct;27(10):347-355. doi: 10.1097/FPC.0000000000000298.
5
Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.在综合医疗保健系统中，非瓣膜性心房颤动患者的华法林管理和结局。
J Manag Care Spec Pharm. 2017 Jun;23(6):700-712. doi: 10.18553/jmcp.2017.23.6.700.
6
Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study.伊朗德黑兰非瓣膜性心房颤动患者接受华法林治疗的治疗范围内时间（TTR）评估：一项横断面研究
J Clin Diagn Res. 2016 Sep;10(9):FC04-FC06. doi: 10.7860/JCDR/2016/21955.8457. Epub 2016 Sep 1.
7
Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice.临床实践中，非瓣膜性心房颤动患者抗栓治疗相关的卒中与出血风险
J Am Heart Assoc. 2015 Jul 17;4(7):e001921. doi: 10.1161/JAHA.115.001921.
8
Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital.匈牙利某县级医院心房颤动患者使用维生素K拮抗剂的口服抗凝治疗及出血事件
Med Sci Monit. 2015 Feb 17;21:518-25. doi: 10.12659/MSM.892360.